Clinical adjudication approach for rapid diagnostics aiming to identify bacteria directly from blood
Infections detected by blood cultures pose a major threat to short- and long-term mortality (1). Early adequate antibiotic therapy—treatment targeting the causative pathogen—confers a survival benefit (2). To maximize likelihood of effective antibiotic coverage for several days until the offending bacterium is identified and susceptibilities reported, providers often prescribe multiple broad-spectrum empiric antibiotics. Consequently, patients face risks of antibiotic-associated adverse events and selection for drug-resistant microbes (3).
Authors
- Kerryl E. Greenwood‐Quaintance (ORCID: https://orcid.org/0000-0003-3760-4310)
- Vance G. Fowler (ORCID: https://orcid.org/0000-0002-8048-0897)
- Robin Patel (ORCID: https://orcid.org/0000-0001-6344-4141)
- Nyssa Schwager
- Sarah B. Doernberg (ORCID: https://orcid.org/0000-0003-1727-6014)
- Scott Evans (ORCID: https://orcid.org/0000-0003-3186-172X)
- Donald Mau
- David Jensen (ORCID: https://orcid.org/0000-0003-2368-3492)
- Lauren Komarow
- Sara E. Cosgrove
Institutions
- Milken Institute (US)
- Mayo Clinic (US)
- Johns Hopkins University (US)
- Duke University (US)
- University of California, San Francisco (US)
- George Washington University (US)
- Johns Hopkins Medicine (US)
- Clinical Research Institute (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Clinical Microbiology and Infection
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1016/j.cmi.2025.12.007
- Primary Topic
- Bacterial Identification and Susceptibility Testing
- Type
- article
- Field-Weighted Citation Impact
- 0.00